CDK4/6 Inhibitors Administration Checklist

**ABEMACICLIB**
- Perform comprehensive review of current medications.
  - Any CYP3A4 inducers or inhibitors?
- Obtain complete blood count (CBC).
  - Prior to first treatment
  - Every 2 weeks for the first 2 months
  - Monthly for the next 2 months
- Perform liver function test (LFT).
  - Prior to treatment
  - Every 2 weeks for the first 2 months
  - Monthly for the next 2 months
- Evaluate for esophagitis or inability to swallow pills.
- Evaluate for pregnancy.
- Assess risk for adherence.
- Instruct patient at the first sign of loose stool to initiate antidiarrheal therapy.
- Patient education: expected adverse reactions and when to notify your healthcare provider

**PALBOCICLIB**
- Perform comprehensive review of current medications.
  - Any CYP3A4 inducers or inhibitors?
- Obtain complete blood count (CBC).
  - Prior to first treatment
  - At the beginning of each cycle
  - Day 15 of the first 2 cycles
- Obtain baseline electrocardiogram (ECG).
  - Prior to first treatment
  - Day 14 of the first cycle
  - At the beginning of the second cycle
- Perform liver function test (LFT).
  - Prior to treatment
  - Every 2 weeks for the first 2 months
  - At the beginning of the subsequent 4 cycles
- Evaluate for esophagitis or inability to swallow pills.
- Evaluate for pregnancy.
- Assess risk for adherence.
- Patient education: expected adverse reactions and when to notify your healthcare provider

**RIBOCICLIB**
- Perform comprehensive review of current medications.
  - Any CYP3A4 inducers or inhibitors?
  - Any medications that can prolong QTc interval?
- Obtain complete blood count (CBC).
  - Prior to treatment
  - Every 2 weeks for the first 2 months
  - At the beginning of the subsequent 4 cycles
- Monitor electrolytes at the beginning of each cycle for 6 cycles
- Obtain baseline electrocardiogram (ECG).
  - Prior to first treatment
  - Day 14 of the first cycle
  - At the beginning of the second cycle
- Perform liver function test (LFT).
  - Prior to treatment
  - Every 2 weeks for the first 2 months
  - At the beginning of the subsequent 4 cycles
- Evaluate for esophagitis or inability to swallow pills.
- Evaluate for pregnancy.
- Assess risk for adherence.
- Patient education: expected adverse reactions and when to notify your healthcare provider

If clinically indicated, tests might not follow exact schedule. (Eli Lilly and Company, 2017; Novartis, 2017; Pfizer Inc., 2017)